Abstract
Phosphorylation is essential for tumor-induced angiogenesis, but how it affects angiogenesis remains unclear. We introduced phosphorylation-related genes from the lung adenocarcinoma dataset, screened out the most characteristic genes PBK through various machine learning methods, and repeatedly verified their survival data, mutation frequency, and clinical information. Subsequently, we conducted a comprehensive analysis of whole cancer based on lung adenocarcinoma, analyzed 33 cases of pan-cancer by GSEA enrichment, screened out a variety of angiogenesis-related pathways, and analyzed the correlation between related risk difference genes and pan-cancer PBK. Finally, we cultured HUVEC cells to simulate the tumor microenvironment and verify cell phenotypic experiments such as cell proliferation, migration, and cell cycle. Finally, it was proved that PBK can affect tumor angiogenesis and the differentiation of Treg cells.
Introduction
Lung adenocarcinoma (LUAD) is a leading cause of cancer-related mortality worldwide, often characterized by late-stage diagnosis and poor prognosis. A critical driver of tumor progression is angiogenesis—the formation of new blood vessels that supply the tumor with nutrients and oxygen. While anti-angiogenic therapies exist, resistance is common, highlighting a need to understand the underlying molecular mechanisms.
Phosphorylation serves as a fundamental regulatory "switch" in cellular signaling. This study investigates how phosphorylation-related genes influence the LUAD microenvironment. Through integrated bioinformatics and experimental validation, the researchers identified PBK (PDZ-binding kinase) as a central regulator that not only promotes angiogenesis but also facilitates immune evasion by recruiting immunosuppressive cells.
Methods
The study utilized a comprehensive "dry-lab to wet-lab" workflow:
- Bioinformatics Screening: Phosphorylation-related genes were extracted from the TCGA-LUAD dataset. Machine learning techniques, including LASSO regression, Random Forest, and univariate Cox regression, were applied to identify genes with the highest prognostic significance.
- Pan-Cancer and Single-Cell Analysis: The role of PBK was evaluated across 33 cancer types using GSEA and TIMER 2.0. Single-cell RNA sequencing data from the TISCH database (e.g., EMTAB6149) were analyzed to determine cell-specific expression patterns.
- Experimental Validation: Functional assays were performed using HUVEC and LUAD cell lines. PBK expression was silenced via shRNA knockdown to observe effects on cell proliferation (CCK-8), migration (wound healing), and angiogenesis (tube formation).
Results
PBK as a Prognostic Marker and Driver of Angiogenesis
High PBK expression was consistently linked to poorer overall survival and progression-free intervals in LUAD and several other malignancies. Pan-cancer analysis revealed that PBK expression positively correlates with Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI), markers of genomic instability and aggressive tumor behavior.
Single-Cell Resolution and the Tumor Microenvironment
Single-cell analysis pinpointed PBK expression within specific cell populations of the tumor microenvironment. Notably, PBK was highly expressed in Regulatory T cells (Tregs) and endothelial cells. This suggests that PBK contributes to an "immune-cold" environment by promoting Treg differentiation, which suppresses the body's natural anti-tumor immune response.
Experimental Validation of PBK Function
In vitro experiments confirmed the bioinformatics predictions. Silencing PBK in HUVEC cells significantly impaired their ability to proliferate and form tube-like structures, effectively inhibiting angiogenesis. Furthermore, PBK knockdown led to cell cycle arrest, demonstrating its necessity for the rapid multiplication of cells within the tumor infrastructure.
Discussion
This study positions PBK as a dual-threat in lung adenocarcinoma, driving both the physical growth of the tumor through angiogenesis and its protection from the immune system via Treg recruitment. The predominantly cytoplasmic localization of PBK makes it an attractive target for small-molecule inhibitors.
While these findings are robust, further research is needed to map the exact downstream signaling pathways through which PBK influences Treg differentiation. Additionally, moving from cell culture models to in vivo animal studies will be crucial for validating PBK as a viable therapeutic target in clinical settings.
Conclusion
PBK is a high-accuracy prognostic biomarker and a pivotal regulator of the LUAD microenvironment. By targeting PBK, it may be possible to simultaneously starve tumors of their blood supply and "re-heat" the immune environment, offering a multi-pronged approach to treating advanced lung cancer.
Summary updated